

## TOTAL PRODUCTION

Nom de l'équipe : Integrative cancer immunology

Nom du directeur pour le contrat en cours : GALON Jérôme

Nom du directeur pour le prochain contrat: GALON Jérôme

## I. PRODUITS DE LA RECHERCHE

*Publications made in collaboration with other teams of the CRC are flagged with ■*

*Publications of staff recruited during the last five years and done in their previous team are flagged with ➡*

### 1. Journaux / revues

#### Articles scientifiques

Mlecnik B, Van den Eynde M, Bindea G, Church SE, Vasaturo A, Fredriksen T, Lafontaine L, Haicheur N, Marliot F, Debetancourt D, Pairet G, Jouret-Mourin A, Gigot JF, Hubert C, Danse E, Dragean C, Carrasco J, Humblet Y, Valge-Archer V, Berger A, Pagès F, Machiels JP, Galon J\*  
Comprehensive immune quantification shows metastasis heterogeneity and major impact of Immunoscore on survival  
J Nat Cancer Inst. 2017 *in press*

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AH, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EM, Bicciano S, Galon J, Murray PJ, Bronte V.  
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.  
Cancer Cell. 2016 Sep 12;30(3):377-90.

Mlecnik B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, Church SE, Maby P, Vasaturo A, Angelova M, Fredriksen T, Mauger S, Berger A, Speicher MR, Pagès F, Valge-Archer V, Galon J\*  
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.  
Science Transl. Med. 2016 24;8(327):327ra26.

■ Mlecnik B, Bindea G, Angell AK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, Sasso M, Bilocq AM, Obenauf AC, Hamieh M, Berger A, Bruneval P, Tuech JJ, Sabourin JC, Le Pessot F, Rafii A, Laurent-Puig P, Speicher MR, Trajanoski Z, Pierre Michel P, Sesboüe R, Frebourg T, Pagès F, Viia Valge-Archer V, Latouche JB, Galon J\*  
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.  
Immunity. 2016 Mar 15;44(3):698-711.

Church SE, Galon J\*  
Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse.  
Immunity. 2015 Oct 20;43(4):631-3.

Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J\*, Preusser M\*

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases  
Oncoimmunology. 2016 Jan 8;5(1)

Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, Waldner MJ, Bindea G, Mlecnik B, Galon J, Trajanoski Z.

Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy.  
Genome Biol. 2015 Mar 31;16(1):64

Maby P, Tougeron D, Hamieh M, Mlecnik B, Kora H, Bindea G, Angell HK, Fredriksen T, Elie N, Fauquembergue E, Drouet A, Leprince J, Benichou J, Mauillon J, Le Pessot F, Sesboué R, Frebourg T, Galon J, Latouche JB.

Correlation between density of CD8+ T cell infiltrates in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy.  
Cancer Res. 2015 Sep 1;75(17):3446-55

■ Stoll G, Bindea G, Mlecnik B, Galon J, Zitvogel L, Kroemer G.

Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies.  
Oncotarget. 2015 May 20;6(14):11894-909.

Mlecnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, Fredriksen T, Lafontaine L, Bilocq AM, Kirilovsky A, Tosolini M, Waldner M, Berger A, Fridman WH, Rafii A, Valge-Archer V, Pagès F, Speicher MR, Galon J.\*

Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients.  
Science Transl. Med. 2014 Mar 19;6(228)

■ Stoll G, Enot D, Mlecnik B, Galon J, Zitvogel L, Kroemer G. Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy.  
Oncoimmunology. 2014 Jan 1;3(1):e27884.

Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, Kirilovsky A, Lagorce C, Bindea G, Ferariu D, Danciu M, Bruneval P, Scripcariu V, Chevallier JM, Zinzindohoué F, Berger A, Galon J, Pagès F. Prognostic and predictive values of the immunoscore in patients with rectal cancer.  
Clin Cancer Res. 2014 Apr 1;20(7):1891-9.

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell HK, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pagès F, Speicher MR, Trajanoski Z, Galon J\*

Spatio-temporal dynamics of intratumoral cells reveal the immune landscape in human cancer  
Immunity. 2013 Oct 17;39(4):782-95. (IF: 20.72)

Galon J\*, Angell HK, Bedognetti D, and Marincola F

The continuum of cancer immunosurveillance: prognostic, predictive and mechanistic signatures  
Immunity. 2013 July 39(1), 11-26 (IF: 20.72)

Bindea G, Galon J\*, Mlecnik B.

CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data.  
Bioinformatics. 2013 Mar 1;29(5):661-3.

### Articles de synthèse / revues bibliographiques

■ Buqué A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.  
Oncoimmunology. 2016 Mar 10;5(6):e1149674.

Kaufman HL, Butterfield LH, Coulie PG, Demaria S, Ferris RL, Galon J, Khleif SN, Mellman I, Ohashi PS, Overwijk WW, Topalian SL, Marincola FM.

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule.  
J Immunother Cancer. 2016 Jun 21;4:37.

Ferris RL, Galon J\*.

Additional Support for the Introduction of Immune Cell Quantification in Colorectal Cancer Classification.  
J Natl Cancer Inst. 2016 May 12;108(8).

Maby P, Galon J, Latouche JB.

Frameshift mutations, neoantigens and tumor-specific CD8(+) T cells in microsatellite unstable colorectal cancers. *Oncoimmunology*. 2015 Nov 24;5(5):e1115943.

Kirilovsky A, Marliot F, El Sissy C, Haicheur N, Galon J, Pagès F.

Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. *Int Immunol*. 2016 Apr 27. pii: dxw021.

■ Iribarren K, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Špišek R, Zitvogel L, Kroemer G, Galluzzi L.

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. *Oncoimmunology*. 2015 Sep 2;5(3):e1088631.

■ Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, Preville X, Sautès-Fridman C, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Trial Watch-Oncolytic viruses and cancer therapy. *Oncoimmunology*. 2015 Dec 8;5(2):e1117740.

■ Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Trial Watch-Immunostimulation with cytokines in cancer therapy. *Oncoimmunology*. 2015 Dec 8;5(2):e1115942.

Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

*J Transl Med*. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. *Nat Rev Cancer*. 2015 Oct 23;15(11):668-79.

Teng MW, Galon J, Fridman WH, Smyth MJ.

From mice to humans: developments in cancer immunoediting. *J Clin Invest*. 2015 Sep;125(9):3338-46.

■ Aranda F, Buqué A, Bloy N, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Trial Watch: Adoptive cell transfer for oncological indications. *Oncoimmunology*. 2015 May 5;4(11):e1046673.

■ Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Trial watch: Naked and vectored DNA-based anticancer vaccines. *Oncoimmunology*. 2015 Apr 2;4(5).

■ Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Trial Watch: Peptide-based anticancer vaccines. *Oncoimmunology*. 2015 Jan 9;4(4):

■ Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. *Oncoimmunology*. 2015 Mar 2;4(4):

■ Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.

Oncoimmunology. 2015 Mar 2;4(4).

■ Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. *Oncoimmunology*. 2015 Feb 3;4(1):e985940.

■ Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L. Consensus guidelines for the detection of immunogenic cell death. *Oncoimmunology*. 2014 Dec 13;3(9):e955691.

■ Bloy N, Pol J, Manic G, Vitale I, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Radioimmunotherapy for oncological indications. *Oncoimmunology*. 2014 Dec 13;3(9):e954929.

■ Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based anticancer therapy. *Oncoimmunology*. 2014 Dec 21;3(11):e963424.

Galon J\*, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pagès F. Towards the introduction of the Immunoscore in the classification of malignant tumors. *J Pathol*. 2014 Jan;232(2):199-209.

■ Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. Classification of current anticancer immunotherapies. *Oncotarget*. 2014 Dec 30;5(24):12472-508.

■ Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Oncolytic viruses for cancer therapy. *Oncoimmunology*. 2014 Jun 1;3:e28694.

■ Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists in oncological indications. *Oncoimmunology*. 2014 Aug 1;3:e29179.

■ Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immunostimulatory cytokines in cancer therapy. *Oncoimmunology*. 2014 Jun 3;3:e29030.

■ Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. *Oncoimmunology*. 2014 May 1;3:e28344.

Zinzindohoué F, Zeitoun G, Berger A, Tosi AM, Marliot F, Lagorce C, Galon J, Pagès F. [Immunology and personalized medicine in oncology]. *Bull Cancer*. 2014 Jun;101 Suppl 1:S12-7.

Galon J\*, Bindea G, Mlecnik B, Angell H, Lagorce C, Tosi AM, Berger A, Pagès F. [Intratumoral immune microenvironment and survival: the immunoscore].  
Med Sci (Paris). 2014 Apr;30(4):439-44.

■ Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Fridman W, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: DNA vaccines for cancer therapy.  
Oncoimmunology. 2014 Jan 1;3(1):e28185.

■ Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Chemotherapy with immunogenic cell death inducers.  
Oncoimmunology. 2014 Jan 1;3(1):e27878.

Bindea G, Mlecnik B, Angell HK, Galon J\*. The immune landscape of human tumors: Implications for cancer immunotherapy.  
Oncoimmunology. 2014 Jan 1;3(1):e27456.

■ Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.  
Oncoimmunology. 2014 Jan 1;3(1):e27297.

■ Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.  
Oncoimmunology. 2014 Jan 1;3(1):e27048.

■ Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Peptide vaccines in cancer therapy.  
Oncoimmunology. 2013 Dec 1;2(12):e26621.

■ Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Lenalidomide-based immunochemotherapy.  
Oncoimmunology. 2013 Nov 1;2(11):e26494.

■ Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Anticancer radioimmunotherapy.  
Oncoimmunology. 2013 Sep 1;2(9):e25595.

■ Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based interventions for cancer therapy.  
Oncoimmunology. 2013 Oct 1;2(10):e25771.

■ Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists for cancer therapy.  
Oncoimmunology. 2013 Aug 1;2(8):e25238.

■ Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory cytokines.  
Oncoimmunology. 2013 Jul 1;2(7):e24850.

■ Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Oncolytic viruses for cancer therapy.  
Oncoimmunology. 2013 Jun 1;2(6):e24612.

■ Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for anticancer immunotherapy.  
Oncoimmunology. 2013 May 1;2(5):e24238.

■ Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy.  
Oncoimmunology. 2013 Apr 1;2(4):e23803.

Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenart P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"

J Transl Med. 2013 Jun 3;11(1):137.

■ Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L.

Trial watch: Chemotherapy with immunogenic cell death inducers.

Oncoimmunology. 2013 Mar 1;2(3):e23510.

Angell H, Galon J\*.

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer.

Curr Opin Immunol. 2013 Apr;25(2):261-7.

■ Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L.

Trial watch: Monoclonal antibodies in cancer therapy.

Oncoimmunology. 2013 Jan 1;2(1):e22789.

Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A, Marincola FM, Ciliberto G, Galon J, Fox BA.

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.

J Transl Med. 2013 Mar 3;11:54.

■ Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Trial watch: Peptide vaccines in cancer therapy.

Oncoimmunology. 2012 Dec 1;1(9):1557-1576.

■ Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Trial watch: Prognostic and predictive value of the immune infiltrate in cancer.

Oncoimmunology. 2012 Nov 1;1(8):1323-1343.

■ Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.

Trial watch: Dendritic cell-based interventions for cancer therapy.

Oncoimmunology. 2012 Oct 1;1(7):1111-1134.

■ Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Oncoimmunology. 2012 Sep 1;1(6):894-907.

■ Fridman WH, Dieu-Nosjean MC, Pagès F, Cremer I, Damotte D, Sautès-Fridman C, Galon J.

The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact.

Cancer Microenviron. 2012 Oct 30. [Epub ahead of print]

Galon J\*, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Hartmann A, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA.

Cancer classification using the Immunoscore: a worldwide task force.

J Transl Med. 2012 Oct 3;10(1):205.

Charoentong P, Angelova M, Efremova M, Gallasch R, Hackl H, Galon J, Trajanoski Z.

Bioinformatics for cancer immunology and immunotherapy.

Cancer Immunol Immunother. 2012 Nov;61(11):1885-903.

■ Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.

Oncoimmunology. 2012 Aug 1;1(5):699-716.

■ Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G.

Trial Watch: Immunostimulatory cytokines.

Oncoimmunology. 2012 Jul 1;1(4):493-506.



- Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.  
Trial Watch: Adoptive cell transfer immunotherapy.  
Oncoimmunology. 2012 May 1;1(3):306-315.
- Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G.  
Trial watch: Chemotherapy with immunogenic cell death inducers.  
Oncoimmunology. 2012 Mar 1;1(2):179-188.
- Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G.  
Trial Watch: Monoclonal antibodies in cancer therapy.  
Oncoimmunology. 2012 Jan 1;1(1):28-37.
- Emens LA, Silverstein SC, Khleif S, Marincola FM, Galon J\*.  
Toward integrative cancer immunotherapy: targeting the tumor microenvironment.  
J Transl Med. 2012 Apr 10;10:70.
- Fridman WH, Pagès F, Sautès-Fridman C, Galon J\*.  
The immune contexture in human tumours: impact on clinical outcome.  
Nat Rev Cancer. 2012 Mar 15;12(4):298-306. doi: 10.1038/nrc3245.
- Galon J\*, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA.  
The immune score as a new possible approach for the classification of cancer.  
J Transl Med. 2012 Jan 3;10:1.

## 2. Colloques / congrès, séminaires de recherche

### Articles publiés dans des actes de colloques / congrès

- Focus on the Immunoscore and its potential clinical implications  
By: El Sissy, Carine; Marliot, Florence; Haicheur, Nacilla; et al.  
ANNALES DE PATHOLOGIE Volume: 37 Issue: 1 Pages: 29-38 Published: FEB 2017
- Characterization of the immunoscore of synchronous resected primary tumor and liver colorectal cancer metastases  
By: van den Eynde, M.; Mlecnik, B.; Bindea, G.; et al.  
Conference: 41st Congress of the European-Society-for-Medical-Oncology (ESMO) Location: Copenhagen, DENMARK  
Date: OCT 07-11, 2016  
Sponsor(s): European Soc Med Oncol  
ANNALS OF ONCOLOGY Volume: 27 Supplement: 6 Meeting Abstract: 573P Published: OCT 1 2016
- Characterization of the evolution of immune response in lung squamous carcinogenesis  
By: Mascaux, Celine; Angelova, Mihaela; Beane, Jennifer; et al.  
Conference: AACR 107th Annual Meeting on Bioinformatics and Systems Biology Location: New Orleans, LA Date: APR 16-20, 2016  
Sponsor(s): Amer Assoc Canc Res  
CANCER RESEARCH Volume: 76 Supplement: 14 Meeting Abstract: 1419 Published: JUL 2016
- Towards personalized cellular adoptive immunotherapy targeting tumor specific neo-antigens in microsatellite unstable colorectal cancers  
By: Maby, Pauline; Hamieh, Mohamad; Kora, Hafid; et al.  
CANCER IMMUNOLOGY RESEARCH Volume: 4 Issue: 1 Supplement: S Meeting Abstract: A114 Published: JAN 2016
- Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014  
By: Ascierto, Paolo A.; Atkins, Michael; Bifulco, Carlo; et al.  
JOURNAL OF TRANSLATIONAL MEDICINE Volume: 13 Article Number: 374 Published: NOV 30 2015
- Metastatic colorectal cancer has heterogeneous immune microenvironment and mutational expression  
By: Van den Eynde, M.; Mlecnik, B.; Bindea, G.; et al.  
Conference: European Cancer Congress Location: Vienna, AUSTRIA Date: 2015

EUROPEAN JOURNAL OF CANCER Volume: 51 Supplement: 3 Pages: S385-S385 Meeting Abstract: 2154  
Published: SEP 2015

Prognostic association of FoxP3 regulatory T cells with tumor infiltrating CD8 cytotoxic T cells quantified on resected liver colorectal metastases (LCM).

By: Van Den Eynde, Marc; Mlecnik, Bernhard; Machiels, Jean-Pascal H.; et al.

Conference: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Location: Chicago, IL Date: MAY 29-JUN 02, 2015

JOURNAL OF CLINICAL ONCOLOGY Volume: 33 Issue: 15 Supplement: S Meeting Abstract: e14643 Published: MAY 20 2015

Characterization of the immune microenvironment of synchronous primary tumor and liver colorectal metastases

By: Van Den Eynde, Marc; Mlecnik, Bernhard; Machiels, Jean-Pascal H.; et al.

Conference: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Location: Chicago, IL Date: MAY 29-JUN 02, 2015

JOURNAL OF CLINICAL ONCOLOGY Volume: 33 Issue: 15 Supplement: S Meeting Abstract: 3610 Published: MAY 20 2015

Preoperative treatment to modify the immune microenvironment of liver colorectal metastases.

By: Van den Eynde, Marc; Mlecnik, Bernhard; Machiels, Jean-Pascal H.; et al.

Conference: Gastrointestinal Cancers Symposium Location: San Francisco, CA Date: JAN 15-17, 2015

JOURNAL OF CLINICAL ONCOLOGY Volume: 33 Issue: 3 Supplement: S Meeting Abstract: 602 Published: JAN 20 2015

From the immune contexture to the Immunoscore in cancer

By: Galon, J.

EUROPEAN JOURNAL OF CANCER Volume: 50 Supplement: 5 Pages: S8-S8 Meeting Abstract: 30 Published: JUL 2014

Place de l'immunologie dans la medecine personnalisee en cancerologie.

[Immunology and personalized medicine in oncology].

By: Zinzindohoue, Franck; Zeitoun, Guy; Berger, Anne; et al.

Bulletin du cancer Volume: 101 Suppl 1 Pages: S12-7 Published: 2014-Jun

CXCL13-CXCR5 Signaling Is Required for the Anti-Tumor Immune Response in Colorectal Cancer

By: Waldner, Maximilian J.; Bindea, Gabriela; Mlecnik, Bernhard; et al.

Conference: 55th Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT) / Digestive Disease Week (DDW) Location: Chicago, IL Date: MAY 03-06, 2014

GASTROENTEROLOGY Volume: 146 Issue: 5 Supplement: 1 Pages: S131-S131 Meeting Abstract: 779 Published: MAY 2014

Intratumoral immune microenvironment and survival: the immunoscore

By: Galon, Jerome; Bindea, Gabriela; Mlecnik, Bernhard; et al.

M S-MEDICINE SCIENCES Volume: 30 Issue: 4 Pages: 439-444 Published: APR 2014

T-cell infiltration (TCI) observed on whole liver colorectal metastases (LCM) resected after preoperative treatment is a prognostic survival factor

By: Van den Eynde, M.; Mlecnik, B.; Machiels, J. P.; et al.

EUROPEAN JOURNAL OF CANCER Volume: 49 Supplement: 4 Pages: S28-S29 Meeting Abstract: MC13-0059 Published: NOV 2013

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"

By: Ascierto, Paolo A.; Grimaldi, Antonio M.; Acquavella, Nicolas; et al.

JOURNAL OF TRANSLATIONAL MEDICINE Volume: 11 Article Number: 137 Published: JUN 3 2013

Prognostic Markers of the Immune System - Immune Infiltration Into the Tumour

By: Galon, J.

Conference: 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Location: European Org Res & Treatment Canc (EORTC), Dublin, IRELAND Date: NOV 06-09, 2012

Sponsor(s): Natl Canc Inst (NCI); Amer Assoc Canc Res (AACR); Novartis Oncol; TAIHO; Johnson&Johnson, Janssen Pharmaceut Co

EUROPEAN JOURNAL OF CANCER Volume: 48 Supplement: 6 Pages: 7-8 Meeting Abstract: 11 Published: NOV 2012

Positive immunosuppressive mechanisms correlate with adaptive immune reaction and survival

By: Angell, H. K.; Mlecnik, B.; Bindea, G.; et al.



Conference: European Congress of Immunology Location: Glasgow, SCOTLAND Date: SEP 05-08, 2012  
IMMUNOLOGY Volume: 137 Special Issue: SI Supplement: 1 Pages: 615-615 Published: SEP 2012

### 3. Développements instrumentaux et méthodologiques

#### Prototypes et démonstrateurs

*La liste de ces produits de la recherche n'a pas à être exhaustive. On mettra en évidence les réalisations les plus significatives.*

#### Plateformes et observatoires

We built the Immunomonitoring and Immunoscore® routine platform at the European Georges Pompidou Hospital (HEGP). All necessary equipments (cryostat, autostainer, scanner, digital analyser, servers, ...) were acquired. A National prospective multicentric study to validate the prognostic value of Immunoscore® was initiated (PHRC Immucol 2012). Samples from 6 hospitals are centralized, and our platform is performing routinely the Immunoscore® assays. Results of the prospective study are expected in 2018.

### 4. Produits et outils informatiques

#### Logiciels

Three software have been developed.

*ClueGO*: This software has been downloaded more than 55,000 times worldwide, and it is the **Top1 most downloaded** software among the more than 500 deposited online (USCD, USA). We published it in Bindea G, et al. *Bioinformatics* 2009.

*CluePedia*: This software has been downloaded more than 32,000 times worldwide, and it is the **Top4 most downloaded** software among the more than 500 deposited online (USCD, USA). We published it in Bindea G, et al. *Bioinformatics* 2013.

*Immunoscore Analyzer*: This software was developed in partnering with Definiens to perform our standardized Immunoscore assay.

#### Bases de données / cohortes

We have multiple collaborations with clinical partners, including the Service of Digestive Surgery, Laënnec-HEGP hospital, (inclusion from 1986 till present), as well as the Avicenne hospitals, from Besançon, Graz (Austria), Erlangen (Germany) St Luc Clinic Bruxelles (Belgium). All data (samples, clinical data and follow-up information) were included into the database (TME.db) that we have created and which received the CNIL agreement (CNIL 2004, CNIL 2010, Permission N° 903434). The computerized data base which was initiated (TME.db) stores more than 2 million parameters. Our cohorts and the associated equipment were declared to INSERM, AP-HP and ministry (2010). Ethical evaluations were accomplished and approved by the expert committees (CPP 2004, CPP 2010, CPP2017).

1)- Cohort study : PHRC 2011 - Inca translational. The team has initiated a national multi-centric network for the prospective evaluation of the immunoscore in colorectal cancer with 6 hospitals (Paris, Bobigny, Rouen, Dijon, Poitiers, Besançon). This PHRC is coordinated by Pr F Pagès.

2)- Worldwide Immunoscore consortium: The cohort is composed of colorectal cancer patients collected from 23 centers from 17 countries from Asia, Europe, North America, Australia, and Middle East, (Austria, Australia, Belgium, Canada, China, Czech republic, France, Germany, India, Italy, Japan, Netherlands, Qatar, Spain, Sweden, Switzerland, and USA) agreed to participate in this process, and to use the Immunoscore following our guideline. This represents a major effort to promote the Immunoscore has a worldwide routine marker and novel way to classify cancer patients. (Principal Investigator: J Galon).

3)- European Immunoscore consortium: The cohort is composed of colorectal cancer patients collected from 5 countries (France, Germany, The Netherland, Italy, Spain) (Principal Investigator: J Galon).

### 5. Brevets, licences et déclarations d'invention

The Valorisation of Immunoscore and the multiple associated patents results in a regular conference call (1 / week, as well as regular physical meetings) with INSERM-Transfert and the Plassereau patent office.

- The laboratory has produced more than 30 patents and patent applications (2005, 2010, 2011, 2012, 2015, 2016, 2017), 05 292 200.2; 60/764,356; 06 809 203.0; 06 809 203.0; 10 156 219.7; 06 809 203.0; 06 809 203.0; 06 809 203.0; 06 809 203.0; 2008 536150; 12/090,832; PCT/IB2006/003168; 11180206.2; 11180207.0; 11180211.2; 11180209.6; 11180205.4; 11180204.7; 11180210.4; 11180205.4; 10 306 329.3; 61/434,498; PCT/EP2011/071530; 11 305 024.9; 61/434 514; 10 306 329.3; 61/434,498; PCT/EP2011/071530; 11 305 024.9; 61/434 514; An in vitro method for the prognosis of progression of a cancer. Galon J et coll. 2005, EU #05292200.2, US #2009-0215053, WO #WO2007/045996, JP #2008-536150. Method for predicting the outcome of a cancer by analysing miRNA expression. Galon J et coll. 2010, EU #10306329.3, US #61/434,498. Method for predicting the outcome of a cancer by analysing gene expression. Galon J et coll. 2011, EU #11305024.9, US # 61/434514, n° 14/695 398 (US), n° 2646571 / n° 11790625.5 (EU), 14/837 271 (US), 2013-541356 (US), N° 14/413 856 (JP), N° 2014-097087 (JP), n° 12700803.5 (EU), N° 13735334.8 (EU), n° 2013-541356 (JP), 2016-104022 (US). 2016 PCT BIO16147; 2016 PCT BIO15366; 2017 PCT BIO16096; 2017 PCT BIO16095; 2017 PCT BIO16094.

On the basis of our results and our patents I created a company specialized in diagnosis in Immuno-Oncology, HalioDx. My company was established in March 2015, especially to develop and market our Immunoscore test and our signature of immune genes. We obtained financing from private investors (venture capital) and HalioDx took out licenses on my portfolio of patents. After validation of my scientific competition INSERM (25.2), I am Chairman of the Scientific Advisory Board of HalioDx. In May 2017, the company HalioDx already has 110+ full-time employees. Three products derived from our patents have been developed, Immunosign®, Halioseek® and Immunoscore®, which received EMA approval as CD-IVD assay. Many pharmaceutical partners are interested in the services offered by HalioDx and have signed contracts.

The valorisation through our INSERM patents and the evaluation in clinical routine of the prognosis of patients according to our methods will thus allow the transfer of our research work to the patient

## 6. Produits des activités didactiques

### Ouvrages, revues didactiques

El Sissy C, Marliot F, Haicheur N, Kirilovsky A, Scripcariu D, Lagorce-Pagès C, Galon J, Pagès F. Focus on the Immunoscore and its potential clinical implications.

*Ann Pathol.* 2017 Feb;37(1):29-38.

Zinzindohoué F, Zeitoun G, Berger A, Todosi AM, Marliot F, Lagorce C, Galon J, Pagès F. [Immunology and personalized medicine in oncology].

*Bull Cancer.* 2014 Jun;101 Suppl 1:S12-7.

Galon J\*, Bindea G, Mlecnik B, Angell H, Lagorce C, Todosi AM, Berger A, Pagès F. [Intratumoral immune microenvironment and survival: the immunoscore].

*Med Sci (Paris).* 2014 Apr;30(4):439-44.

### E-learning, cours multimedia,

Webinar on 21 July 2016 on Immunoscore <https://vimeo.com/175712207/b75ceea860>

### University teaching

. Pr. F Pagès is elected member of the Board of the University Paris Descartes and of the Scientific Council of the Faculty of Medicine Paris Descartes

. Pr. F Pagès is member of the Education Committee of the Faculty of Medicine Paris Descartes and of the steering committee of the SIRIC CARPEM (Pr P Laurent-Puig).

. He is responsible of Health Master 1 in Immunology for Paris Descartes and Paris Diderot Universities and co-responsible of the 'Diplome Universitaire de thérapies immunologiques, Paris Descartes University, Paris, France

## 7. Produits destinés au grand public

### Émissions radio, TV, presse écrite

#### Radio

Dr. Galon, 1h navigating the cancer maze, interview by Grace Gawler, Brisbane, Australia.

#### French Press:

- **Article du 09/01/2017 de La Tribune** <http://marseille.latribune.fr/innovation/2017-01-09/halioldx-affiche-ses-ambitions.html> « Immunoscope Colon relies directly on patents from the work of research director Jérôme Galon, co-founder of Halioldx. »
- **Article du 26/09/2016 des Echos** [https://www.lesechos.fr/26/09/2016/LesEchos/22284-108-ECH\\_halioldx-lance-son-kit-de-diagnostic-pour-les-cancerologues.htm](https://www.lesechos.fr/26/09/2016/LesEchos/22284-108-ECH_halioldx-lance-son-kit-de-diagnostic-pour-les-cancerologues.htm) « *The company licenses the patent of Inserm researcher Jérôme Galon, who has identified several markers making it possible to count the number of lymphocytes present on the periphery of a tumor.* »
- **Article du 18/08/2016 de Go Met** <http://www.go-met.com/halioldx-lance-immunoscope-test-diagnostic-mieux-traiter-cancer/> « *Jérôme Galon, Research Director at Inserm and Chairman of the Scientific Council of Halioldx, launched four years ago a study of 2,800 patients in 17 countries. The test was able to validate its performance on colon cancer.* »
- **Article du 31/08/2016 de La Tribune** <http://marseille.latribune.fr/innovation/2016-08-31/halioldx-un-test-pour-orienter-le-traitement-du-cancer-du-colon.html> « In detail, "Immunoscope consists of a reaction part, an instrument part and a software part ... and it proves to be better than the usual existing tests." This is indeed what confirmed a recent clinical study carried out on 3 000 subjects, an important first stage of which Jérôme Galon presented the results at the annual meeting of the American Society of Clinical Oncology (Asco) 2016, International scale. "He has demonstrated the good performance of the test, particularly in stages 2 and 3. Further studies will be carried out to better specify the performance of the test and support its reimbursement to health authorities in France, Europe and the USA".
- **Article du 08/08/2016 du Figaro** <https://www.pressreader.com/france/le-figaro/20160708/282213715149017> (en version scan)
- **Article du 05/02/2016 de Buzz Santé** <https://buzzsante.com/sante/cancer/cancer-colorectal-ou-cancer-du-colon/metastases-cancereuses-la-reponse-immunitaire-du-patient-est-determinante> « *"We carried out the most exhaustive examination possible, analyzing all the genetic alterations and using different approaches to characterize the host's immune response as well as possible," specifies Jérôme Galon, who heads the laboratory.* »

#### International Press:

- **Article du 06/09/2016 de Onclive** <http://www.onclive.com/publications/oncology-live/2016/vol-17-no-17/prognostic-tool-for-immuno-age-debuts> « *Today, there is not a single host immune characteristic that is taken into account for cancer patients. We don't know anything about the immune system of a cancer patient because there is not a single standardized assay," Galon said during the presentation. "In the era of immunotherapy, it is becoming essential to start classifying cancer patients based on immune parameters."*
- **Article du 21/08/2016 de Stuff** <http://www.stuff.co.nz/national/health/83347575/dads-cancer-journey-inspires-canterbury-students-phd-research> « *Kennedy is part of an international effort to produce what is called the "immunoscope", a project conceived by French doctor Jérôme Galon in 2006, as an attempt to re-grade the stages based on extra information* »
- **Article du 05/06/2016 de Cancer Therapy Advisor** <http://www.cancertherapyadvisor.com/gastrointestinal-cancers/colon-cancer-immunoscope-prolonged-time-recurrence-high-score/article/500979/> « *"There were at least 4 big hurdles in this study," said lead investigator Jerome Galon, PhD, of INSERM at Cordeliers Research Center in Paris, France, during his presentation. "Heterogeneity of patients between centers; heterogeneity of patient care between countries; heterogeneity of IHC (immunohistochemistry) staining between centers; and heterogeneity of clinical data and follow-up between centers."*
- **Article du 25/02/2016 de The Scientist** <http://www.the-scientist.com/?articles.view/articleNo/45445/title/Mutations-Not-Tied-to-Metastasis/> « *Clearly, the tumor cell [genetic] alterations did not show any relationship with the fact that the tumor developed metastasis," Galon told The Scientist. "The most striking observation was, in fact, the opposite." The only mutation that stood out correlated with an absence of tumor spread.*
- **Article du 24/02/2016 de Genome web** <https://www.genomeweb.com/sequencing-technology/team-ties-tumor-microenvironment-metastasis-colorectal-cancer>

**Produits de vulgarisation : articles, interviews, éditions, vidéos, etc.**

- Video 16/06/2016 de Onclive during ASCO  
<http://www.onclive.com/onclive-tv/jerome-galon-on-the-prognostic-value-of-immunoscore>
- **Validation of the Immunoscore as a Prognostic Marker in Colon Cancer** Cancer Therapy Advisor 4 June 2016 <https://www.youtube.com/watch?v=kZl8H4U6QvY>
- **Accelerating Cancer Immunotherapy 2017** [Wednesday 29th - Thursday 30th March 2017 London, UK](#)  
<https://www.atthelimits.org/multimedia/aci-2017/jerome-galon/>
- **Understand Tumor Progression and Immune Reaction against Cancer by Using Integrative Biology and Bioinformatics** Tel Aviv University, publié en décembre 2015 (CLINAB)  
<https://www.youtube.com/watch?v=oPDlePLyWQ> et <https://www.youtube.com/watch?v=rMK0cmJs-Bc>
- **Biomarkers in t-cell therapy trials, Vidéo de Ecaner.net** publiée en avril 2016  
<https://www.youtube.com/watch?v=MEWMyCG0bQg&t=322s>
- **The Immune Contexture in human cancer** Journée Marseille immunopole/Eurobiomed November 2015  
<https://vimeo.com/channels/9emecarrefoureurobiomed/145977658>

**Débats science et société**

Invitation - **Club de l'Europe** - Dîner-débat du mardi 4 octobre 2016 - "Où en sommes-nous dans l'innovation en oncologie?", Paris, France

Invitation - **Club de l'Europe** - Petit-déjeuner débat - Mercredi 19 juillet 2017 - "La révolution des traitements d'immuno-oncologie : vers la fin du cancer ?", Paris, France

## II. ACTIVITÉS DE RECHERCHE ET INDICES DE RECONNAISSANCE

*La liste de ces activités n'a pas à être exhaustive. On mettra en évidence les activités les plus significatives en termes de rayonnement et d'attractivité, d'interaction avec l'environnement et d'implication dans la formation par la recherche.*

### 1. Activités d'évaluation

**Évaluation d'articles et d'ouvrages scientifiques**

Dr Galon is/was scientific reviewer for **26 scientific journals**, *Including:* American Journal of Pathology, Biochemical and Biophysical Research Communications, Blood, British Journal of Cancer, Cancer Research, European Journal of Immunology, Journal of immunotherapy of cancer, Expert Opinion on Therapeutic Patents, Frontiers in Immunology, Immunology today, Immunity, Journal of Clinical Investigation, Journal of Clinical Oncology, Journal of Digestive and liver disease, Journal of Immunology, Journal of Immunotherapy, Journal of the National Cancer Institute, Lancet Oncology, Molecular and Cellular Biology, Nature, Nature immunology, Nature Genetics, Oncoimmunology, PLoS Biology, Science Translational Medicine, Science.

## Évaluation de projets de recherche

Dr Galon is/was grant reviewer for **13 institutions** both national and international, *including*:

(Agence Nationale de Recherche (ANR), France; Association pour la Recherche sur le Cancer (ARC), France; Institut Merieux, France; Fondazione Cariplo for Research, Italy; Health Research Council (HRC), New Zealand; Fondation pour la Recherche Médicale (FRM), France; Institut National de la Santé et de la Recherche Médicale (INSERM), France; Direction de l'Hospitalisation et de l'Organisation des Soins (DHOS), translational research, France; Programme hospitalier de recherche clinique (PHRC), France; International Association for Cancer Research (UK), United Kingdom; Italian Association for Cancer Research (AIRC), Italy; Ligue Nationale Contre le Cancer, France; Institut National pour le Cancer (INCa), France).

## 2. Activités d'expertise scientifique

### Activités de consultant

Dr Galon is the chairman of the Scientific Advisory Board of HalioDx. Dr Galon has been/is in the Scientific Advisory Board of **14 pharmaceutical or biotech companies**, including 8 in the USA, 4 in Europe and 2 in France. HalioDx (2015-present), Illumina, San Diego, USA (2017-present), Kite Pharma, Los Angeles, USA (2016-present), AMGEN, USA (2016-present), IObiotech, Copenhagen, Denmark (2016-present), Northwest Biotherapeutics, Bethesda, USA (2016-present), BMS, USA (2016-present), Actelion, Basel, Switzerland (2015-present), Novartis, Basel, Switzerland (2015-present), Incyte, USA (2015-present), Astra Zeneca, Maryland, USA (2014-present), MedImmune, Gaithersburg, MD, USA (2013-present), Definiens, Munich, Germany (2015-2016), ImmunID, Lyon, France (2013-2016).

He was/is also consultant for **9 pharmaceutical or biotech companies**, including Mologen, Berlin, Germany (2016-present), Compugen, Israel (2014-present), NanoString, USA (2014-2016), Definiens, Germany (2014-2016), Janssen, Johnson&Johnson, USA (2013-2015), GSK, Collegeville, PA, USA (2013-2015), BMS, Paris, France (2012-2016), Ventana-Roche, Tuscon, AZ, USA (2012-2013), Jounce, Boston, MA, USA (2012-2014).

## 3. Organisation de colloques / congrès

Dr Galon has organized **11 International congresses**, *including*:

Melanoma Bridge conference (2017), 42<sup>nd</sup> ESMO European Cancer Congress (2017), Keystone symposium, Cancer immunotherapy, Vancouver, Canada (2016), International (AACR, EATI, CIMT, CRT) Cancer Immunotherapy Conference, New York, USA (2015), 18<sup>th</sup> ECCO – 40<sup>th</sup> ESMO European Cancer Congress, Vienna, Austria (2015), EATI annual meeting, SITC and Immunoscore congress, Paris, France (2015), 2<sup>nd</sup> International Conference on Immunoscore, Doha, Qatar (2015), SITC Workshop on Tumor Microenvironment, Bethesda, MD, USA (2015), 1<sup>st</sup> International Conference on Immunoscore, Naples, Italy (2015), SITC Workshop on Tumor Microenvironment, Bethesda, MD, USA (2015), 1<sup>st</sup> International Task Force meeting on Immunoscore, Naples, Italy (2015).

## 4. Post-doctorants et chercheurs accueillis

Since 2012, I have directed **19 people**, among former students and post-docs who worked in my laboratory, 6 Technicians, Ingeneers, 2 master students, 2 PhD fellows and 9 Post-Doctoral fellows.

Notably, 1 of my Post-Doctoral fellow was recruited on a permanent position at AstraZeneca (UK), 1 of my Post-Doctoral fellow was recruited on a permanent position at Nanostring (USA), and 1 Post-Doctoral fellow was recruited on a permanent research position (CR1) at Inserm.

These technicians, ingeneers and Post-Doctoral fellows were recruited on 15 national, international or industrial grants. This led to multiple high-impact publications (see publication list).

## 5. Interactions avec les acteurs socio-économiques

### Contrats de R&D avec des industriels

The team has received **6 industrial research grants** since 2012.

Institution	Title	Period	Amount
MedImmune	Tumor microenvironment analysis	2011-2016	1300 k€
MedImmune	Highthroughput comprehensive analysis of colorectal tumors	2016-2019	400 k€
AstraZeneca	Immune biomarkers and Immunoscore in solid tumors	2015-2017	150 k€
IObiotech	Immune biomarkers and Immunoscore in vaccine clinical trials	2015-2016	40 k€
Perkin-Elmer	Multispectral imaging of the tumor microenvironment	2016-2017	20 k€
Janssen	Colon cancer immunology, pre-neoplastic lesions, and IL17 producing cells: biomarkers and therapeutic targets	2015-2018	790 k€

### Attractiveness and collaboration

Galon lab has local collaboration with the Cordeliers Center (Hepatocellular carcinoma and immune response (with Zucman Team), Immunogenic cell death (with Kroemer Team), collaboration with clinical departments from French hospitals (n=9), collaboration with national research labs (n=9), international collaboration on the immune contexture (n=19), and international collaboration Immunoscore (n=22).

### Créations d'entreprises, de start-up

HaliDx – Immuno-Oncology Diagnostic company ([www.haliidx.com](http://www.haliidx.com)) – Co-founder Jérôme Galon

On the basis of our results and our patents I created a company specialized in diagnosis in Immuno-Oncology, HaliDx. My company was established in March 2015, especially to develop and market our Immunoscore test and our signature of immune genes. We obtained financing from private investors (venture capital) and HaliDx took out licenses on my portfolio of patents. After validation of my scientific competition INSERM (25.2), I am Chairman of the Scientific Advisory Board of HaliDx.

- HaliDx vision is to create a leader in Immuno-Oncology diagnostics, the emerging segment of the cancer molecular diagnostic market (MDx).
- Dr. Jérôme Galon is a co-founder of HaliDx. The co-founders are experienced executives with extensive track records in the Diagnostic Industry, Pharma & BioTech Management.
- HaliDx has a unique Immuno-Oncology (I-O) technology. HaliDx licenced a comprehensive patent portfolio from Dr. Jérôme Galon & colleagues (INSERM UMRS1138), covering clinical use of I-O biomarkers, Immunoscore® concept (IHC) & gene expression signatures (MDx), Assays & biomarkers correlated to prognosis and/or response to cancer therapeutics, with patents granted in US, EU and Japan.
- HaliDx was created in January 2015, and has State of the art R&D, manufacturing facilities and expertise, with IVD compliant Quality System / ISO 13 485/ GMP, Fully qualified and trained staff (HaliDx has now more than **110+ FTEs**), and 1800 m<sup>2</sup> of compliant R&D & manufacturing facilities.
- Three products derived from our patents have been developed, Immunosign®, HaliDseek® and Immunoscore®, which received EMA approval as CD-IVD assay. Many pharmaceutical partners are interested in the services offered by HaliDx and have signed contracts.
- HaliDx received two awards: the *Seal of Excellence Certificate* by the European Commission for *Immunoscore® (2016)*, and the award of the 2<sup>nd</sup> edition of the *Worldwide Innovation Challenge*, for its *CD8/PD-L1 HaliDseek® assay (2016)*.

The valorisation through our INSERM patents and the evaluation in clinical routine of the prognosis of patients according to our methods will thus allow the transfer of our research work to the patient.

## 6. Contrats de recherche financés par des institutions publiques ou caritatives

Contrats européens (ERC, H2020, etc.) et internationaux (NSF, JSPS, NIH, Banque mondiale, FAO , etc.)

The team has received 2 european H2020 grants since 2012, including one as coordinator.

In 2017, the team is under second phase evaluation for another H2020 Grant (coordinator: J Galon)

Institution	Title	Period	Amount
H2020-EraNet	Immunoscore in colorectal cancer (Coordinator of European Consortium)	2015-2018	256 k€
H2020-PHC32 APERIM	APERIM: Advanced bioinformatics platform for PERsonalised cancer Immunotherapy	2015-2018	400 k€



**Contrats nationaux (ANR, PHRC, FUI, INCA, etc.)**

The team has received 6 national grants since 2012.

Institution	Title	Period	Amount
LabEX ImmunoOnco	ImmunoOncology	2011-2021	500 k€
SIRIC	Carpem, CAncer Research and PErsonalized Medicine	2012-2017	150 k€
PACRI	Paris Alliance of Cancer Research Institutes	2012-2017	150 k€
PHRC	Immucol: Colorectal cancer: a prospective multicentric study of the in situ immune infiltrate for the identification of the patients at high risk of relapse	2011-2014	100 k€
INCA	Translational research on Immunoscore in colorectal cancer	2014-2017	100 k€
Canceropole	Immunoscore and biomarkers in colorectal cancer	2014-2017	120 k€

**7. Indices de reconnaissance**

**Prix - Distinctions**

Dr Galon received the very prestigious **William B. Coley Award** for Distinguished Research in Basic and Tumor Immunology (Cancer Research Institute, NY, USA, 2010), and by the **Academy of Science** (Simone et Cino del Duca Cancer Research Award, 2011), by the **National Academy of Medicine** (Gallet et Breton award, 2011). In 2014, Dr Galon received the **Jacques Oudin Prize**, for Immunotherapeutic research, from the French Society of Immunology, France. He was selected to give the 2014 Annual **B. Benacerraf Lecture in Immunology, Harvard, USA**.

**Responsabilités dans des sociétés savantes**

Since 2012, Dr Galon has been on the scientific boards of many societies such as the: World Immunotherapy Council (WIC), American Association of Cancer Research (AACR), American Association of Immunology (AAI), French Association of Immunology (SFI). He is in the Board of Directors of the Society for Immunotherapy of Cancer (SITC, USA), and Associate Director and co-founder of the European Academy of Tumor Immunology (EATI).

**Invitations à des colloques / congrès à l'étranger, séjours dans des laboratoires étrangers**

Since 2012, Dr Galon has been invited to speak in 156 international congress/seminars, in 30 different countries.

**Invited Lectures (2012-2017, n=156)**

Dates	Location	Awarding Institution/Conference
Dec 2017	Congress, Sendai, Japan	JSI annual meeting: Immunoscore and pre-existing immunity
Sep 2017	Congress, Suzhou, China	CSH meeting: The Immunoscore
Jul 2017	Congress, Boston, USA	Harvard Evergrande symposium: Immunoscore and immune contexture
Jun 2017	Congress, Erlangen, Germany	PCS meeting: Immunoscore
May 2017	Congress, Saint Malo, France	CCDT 2017: Immunoscore
Apr 2017	Congress, Washington, USA	AACR Annual: Immunoscore and tumor classification
Mar 2017	Congress, Marseille, France	Canceropole PACA: Immunité et cancer : un nouveau paradigme
Mar 2017	Congress, Madrid, Spain	Roche CIT Summit: The Immunoscore as New Approach for Cancer Classification
Mar 2017	Congress, Madrid, Spain	Roche CIT Summit: The Role of Immune Infiltrate in Colorectal Cancer
Mar 2017	Congress, London, UK	ACI meeting: The dynamics of the tumor microenvironment
Mar 2017	Congress, San Antonio, USA	USCAP Annual meeting: The Immunoscore
Feb 2017	Congress, St Andrews, Scotland	Cancer Colloquium XII: Unleashing the pre-existing adaptive immunity from primary and metastatic tumors
Feb 2017	Congress, Paris, France	Académie des Science: Contexture immunitaire et Immunoscore : un nouveau paradigme en cancérologie
Feb 2017	Heidelberg, Germany	EMBL-CCE Congress: Unleashing the pre-existing adaptive

Jan 2017	Congress, Oslo, Norway	immunity
Jan 2017	Congress, Oslo, Norway	BMS symposium: Immunoscore & Cancer
Dec 2016	Congress, Naples, Italy	9 <sup>th</sup> Cancer Crosslinks: Cancer & Inflammation
Nov 2016	Congress, London, UK	Melanoma Bridge meeting: Immunoscore worldwide consortium and beyond
Nov 2016	Congress, Paris, France	RMH meeting: Immunoscore & Cancer
Nov 2016	Congress, N <sup>al</sup> Harbor, USA	50 <sup>th</sup> Annual SFI meeting: From the immune contexture to Immunoscore in the era of cancer immunotherapies
Oct 2016	Congress, Paris, France	SITC Annual Meeting: Combination and Patient Selection
Oct 2016	Congress, Paris, France	SFCE: Immunoscore
Oct 2016	Copenhagen, Denmark	Canceropole: L'Immunoscore comme outil de prédiction de la survie des patients
Oct 2016	Congress, Barcelona, Spain	ESMO Annual meeting: Tumor landscape: Clues for new targets
Sep 2016	Congress, Villejuif, France	Immune profiling world congress 2016: Immunoscore®: An innovative combination of immunohistochemistry and digital pathology-based scoring
Sep 2016	Congress, Krakow, Poland	Immunoradiotherapy meeting: Immune contexture of radiation response
Sep 2016	Congress, Seoul, Korea	ESSO36: Beyond TNM - towards an Immunoscore
Jun 2016	Congress, Basel, Switzerland	ACIS 2016, Asan Cancer Institute Annual symposium: Cancer Classification Using the Immunoscore
Jun 2016	Seminar, Berlin, Germany	CLINAM Annual meeting : Precision medicine in cancer
Jun 2016	Seminar, Paris, France	Novartis: Immunoscore in the era of cancer immunotherapies
Jun 2016	Seminar, Paris, France	National Academy of Medicine: Antibodies and immunity in cancer
Jun 2016	Congress, Chicago, USA	Ozyme: Immunoscore in the era of cancer immunotherapies
Jun 2016	Congress, Jyväskylä, Finland	ASCO Annual meeting : Worldwide Immunoscore consortium results
May 2016	Congress, San Diego, USA	Finnish Cancer Institute congress : Immunoscore in colon cancer
May 2016	Seminar, Boulogne, France	DDW congress: Tumor immunotype and clinical implication
Apr 2016	Congress, New Orleans, USA	Ipsen: Immunoscore in the era of cancer immunotherapies
Apr 2016	Congress, Munich, Germany	AACR Annual meeting : Immunoscore and immune contexture in cancer
Mar 2016	Congress, Boston, USA	ITOC3 congress, prognostic and predictive immune biomarkers
Mar 2016	Congress, Washington, USA	Definiens Symposium, Immune contexture and Immunoscore in cancer
Mar 2016	Congress, Seattle, USA	Cancer immunotherapy workshop: Immunoscore in cancer
Mar 2016	Seminar, Los Angeles, USA	USCAP Annual meeting : Immunoscore in cancer
Mar 2016	Congress, Toulouse, France	Kite: Immunoscore in the era of cancer immunotherapies
Mar 2016	Seminar, Seefeld, Austria	Canceropole, GSO: Liver metastasis and immunity
Jan 2016	Seminar, Philips, Netherland	APERIM H2020 : Tumor genotype and immune response to cancer
Jan 2016	Congress, Vancouver, Canada	Philips: Immunoscore in the era of cancer immunotherapies
Dec 2015	Congress, Milan, Italy	Keystone Symposium, Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies : The Immunoscore
Dec 2015	Congress, Naples, Italy	Innovative therapy, monoclonal antibodies and beyond : Tumor immunity
Nov 2015	Seminar, Bruxelles, Belgium	Melanoma Bridge Annual : Session on Immunoscore
May 2015	Seminar, Marseille, France	Merck : Multidisciplinary symposium in digestive oncology : Tumor immunity
Nov 2015	Congress, Sapporo, Japan	Luminy: Immunoscore in the era of cancer immunotherapies
Nov 2015	Congress, Washington, USA	JSI Annual : Tumor Immunology and Immunoscore
Oct 2015	Seminar, Bale, Switzerland	SITC Annual, Predictive value of Immunoscore
Sep 2015	Congress, New York, USA	Actelion: Immunoscore in the era of cancer immunotherapies
Sep 2015	Congress, Vienna, Austria	AACR-CRI-CIMT-EATI Immunotherapy 1 <sup>st</sup> international congress: Antigenome and immune contexture in cancer
Sep 2015	Congress, Antwerpen, Belgium	ESMO – ECCO European congress: Immunoscore in cancer
Sep 2015	Seminar, Copenhagen, DN	Biomarker summit: Immunoscore in cancer
Jun 2015	Keynote, Basel, Switzerland	IO Biotech: Immunoscore in the era of cancer immunotherapies
Jun 2015	Congress, Sitges, Spain	CLINAM congress: European Summit for Clinical Nanomedicine and Targeted Medicine, Keynote lecture Immunity and cancer
May 2015	Seminar, Marseilles, France	Cell Symposium: Cancer, Inflammation, and Immunity
May 2015	Congress, Washington, USA	Innate: Immunoscore in the era of cancer immunotherapies
Apr 2015	Congress, Philadelphia, USA	AAADV - FDA, Immunotherapy Biomarkers in Anti-cancer Drug Development
Mar 2015	Congress, Cambridge, UK	AACR Annual: Major symposium, Mechanisms of tumor escape
Mar 2015	Congress, Lefka, Greece	CRUK meeting: Immunoscore and cancer immune landscape
Mar 2015	Congress, Paris, France	Roche oncology meeting : Profiling immune landscape in tumors
Feb 2015	Seminar, Seattle, USA	TAT 2015, Targeted Anticancer Therapies: Immunoscore in cancer
		Nanostring: Immunoscore and cancer immune landscape

Feb 2015	Seminar, Boston, <i>USA</i>	MGH: Immunoscore in the era of cancer immunotherapies
Jan 2015	Congress, Paris, <i>France</i>	Amgen cancer meeting: Immunoscore in cancer
Jan 2015	Congress, Paris, <i>France</i>	Vaccine cancer – SFI: Immunoscore and cancer immune landscape
Jan 2015	Congress, Toledo, <i>Spain</i>	HHMT-Ovarian cancer symposium: Immunoscore and immune landscape
Dec 2014	Congress, Kaatsheuvel, <i>NL</i>	Dutch Society of Immunology: Immunoscore in the era of cancer immunotherapies
Dec 2014	Congress, Naples, <i>Italy</i>	Melanoma bridge meeting: Immunoscore
Nov 2014	Congress, Bar Harbor, <i>USA</i>	SITC annual meeting: Immunoscore in the era of cancer immunotherapies
Nov 2014	Congress, Seoul, <i>Corea</i>	KAST Symposium: Immunoscore in the era of cancer immunotherapies
Nov 2014	Seminar, Gaithersburg, <i>USA</i>	MedImmune: Immunoscore in the era of cancer immunotherapies
Oct 2014	Congress, Daejeon, <i>Corea</i>	KAIST Symposium: Immunoscore in the era of cancer immunotherapies
Oct 2014	Keynote, Boston, <i>USA</i>	Keynote speaker for the 2014 Annual Baruj Benacerraf Lecture in Immunology ; Harvard Medical School
Oct 2014	Seminar, Boston, <i>USA</i>	MGH, Harvard: Immunoscore in the era of cancer immunotherapies
Oct 2014	Congress, Washington, <i>USA</i>	FDA/HESI workshop: Immunoscore in the era of cancer immunotherapies
Oct 2014	Congress, San Francisco, <i>USA</i>	Definiens Symposium: Immunoscore in the era of cancer immunotherapies
Sep 2014	Congress, Xian, <i>China</i>	4 <sup>th</sup> Sino-French symposium: Microenvironment and Cancer
Sep 2014	Seminar, Marseille, <i>France</i>	Innate Pharma: Immunoscore in the era of cancer immunotherapies
Jul 2014	San Francisco, <i>USA</i>	Molecular Therapeutics of Cancer Research Conference, Asilomar: The Immunoscore in the era of cancer immunotherapies
Jul 2014	Congress, Munich, <i>Germany</i>	23rd Biennial Congress of the European Association for Cancer Research (EACR): The Immunoscore in cancer
Jun 2014	Keynote, Brisbane, <i>Australia</i>	Keynote speaker for the Kidson Lecture at Berghofer Medical Research Institute (QIMR) in Brisbane
Jun 2014	Keynote, Chicago, <i>USA</i>	Keynote speaker at Cancer Center at Loyola University Medical Center, Chicago
Jun 2014	Congress, Chicago, <i>USA</i>	ASCO Congress faculty invitation. The Immunoscore in the era of cancer immunotherapies
Jun 2014	Keynote, Paris, <i>France</i>	Keynote speaker at EATI/SITC/Immunotherapy and Immunoscore Meeting
Jun 2014	Keynote, Paris, <i>France</i>	Keynote speaker at WIN2014 symposium
May 2014	Congress, Quebec, <i>Canada</i>	Keynote speaker at Canadian Cancer Immunotherapy meeting
May 2014	Congress, Erlangen, <i>Germany</i>	International cancer symposium, The Immunoscore in cancer
May 2014	Seminar, Vitry, <i>France</i>	Sanofi: Immune biomarkers in oncology
Apr 2014	Congress, Rio, <i>Brazil</i>	Keynote speaker at Challenges and Solutions in Cancer Research and Treatment congress
Apr 2014	Congress, Brno, <i>Czech</i>	Oncology Symposium, The Immunoscore in cancer
Mar 2014	Seminar, Bale, <i>Switzerland</i>	Novartis: From the immune contexture to the Immunoscore in the era of cancer immunotherapies
Mar 2014	Congress, Munich, <i>Germany</i>	ITOC1 -Immunotherapy of Cancer Congress, Immunotherapies and Immunoscore in cancer
Mar 2014	Congress, San Diego, <i>USA</i>	AACR Congress, Tumor heterogeneity. The Immunoscore in the era of cancer immunotherapies
Jan 2014	Congress, Doha, <i>Qatar</i>	Tumor immunology symposium: The Immunoscore in cancer
Jan 2014	Seminar, San Francisco, <i>USA</i>	Genentech: The Immunoscore in the era of cancer immunotherapies
Dec 2013	Congress, Paris, <i>France</i>	BMS symposium on melanoma: Cancer immunotherapies
Dec 2013	Congress, Naples, <i>Italy</i>	Melanoma bridge meeting: The Immunoscore in cancer
Nov 2013	Congress, <i>Annecy, France</i>	INCa congress: Immunotherapies and Immunoscore in cancer
Nov 2013	Seminar, Stockholm, <i>Sweden</i>	Karolinska institute: The Immunoscore in the era of cancer immunotherapies
Nov 2013	<i>Geneva, Switzerland</i>	ESMO congress: Biomarkers in cancer
Nov 2013	<i>Washington DC, USA</i>	SITC annual meeting organizer and chairman: Biomarkers in cancer
Nov 2013	Seminar, Paris, <i>France</i>	Pasteur institute: The Immunoscore in the era of cancer immunotherapies
Oct 2013	Congress, St Portrieux, <i>France</i>	BMS symposium on melanoma: Cancer immunotherapies
Oct 2013	Congress, London, <i>UK</i>	TIMCC meeting: From the immune contexture in cancer to the Immunoscore in the era of cancer immunotherapies
Sep 2013	Congress, Copenhagen, <i>Danemark</i>	Cancer society symposium: The immunoscore in cancer
Sep 2013	Congress, Bethesda, <i>USA</i>	Inflammation, microbiota and cancer: Immunoscore in colon cancer
Aug 2013	Congress, Milan, <i>Italy</i>	15 <sup>th</sup> International congress of Immunology: From the immune

		contexture in cancer to the Immunoscope in the era of cancer immunotherapies
Jul 2013	Congress, Paris, <i>France</i>	3 <sup>rd</sup> immunotherapy meeting, EATI: The Immunoscope: prospective evaluation of the immune infiltrate in cancer
Jun 2013	Seminar, Paris, <i>France</i>	Curie institute: The Immunoscope in the era of cancer immunotherapies
May 2013	Congress, Montpellier, <i>France</i>	Siric meeting: The Immunoscope, a new paradigm for cancer
May 2013	Congress, Boston, <i>USA</i>	4 <sup>th</sup> Definiens symposium: From the immune contexture in cancer to the Immunoscope in the era of cancer immunotherapies
May 2013	Congress, Halle, <i>Germany</i>	TIMO IX meeting: The importance of the immune contexture for cancer classification
Apr 2013	Congress, Mandelieu, <i>France</i>	Cancer stem cell meeting: From the immune contexture in cancer to the Immunoscope
Apr 2013	Seminar, Paris, <i>France</i>	Janssen: From the immune contexture in cancer to the Immunoscope in the era of cancer immunotherapies
Mar 2013	Congress, Taormina, <i>Italy</i>	Ipsen Foundation, Cancer immunotherapy meeting: From the immune contexture in cancer to the Immunoscope
Mar 2013	Congress, Stockholm, <i>Sweden</i>	Frontiers in cancer symposium: The Immunoscope: in the era of cancer immunotherapies
Feb 2013	Seminar, London, <i>UK</i>	CRI: From the immune contexture to the Immunoscope
Jan 2013	Seminar, Houston TX, <i>USA</i>	Immune biomarkers: a novel paradigm for colorectal cancer
Jan 2013	Seminar, San Francisco, <i>USA</i>	Genentech: From the immune contexture to the Immunoscope
Jan 2013	Seminar, Mountain view, <i>USA</i>	Ventana, The Immunoscope: in the era of cancer immunotherapies
Jan 2013	Seminar, Essen, <i>Germany</i>	The Immunoscope: a novel paradigm for colorectal cancer
Dec 2012	Congress, Naples, <i>Italy</i>	Worldwide Immunoscope workshop. The Immunoscope
Dec 2012	Seminar, Bern, <i>Switzerland</i>	The Immunoscope: a novel approach for the classification of cancer in the era of immunotherapies
Nov 2012	Congress, Doha, <i>Qatar</i>	NCCCR Cancer Symposium. TNM classification and Immunoscope: T is for T cells and M is for Memory
Nov 2012	Meeting, Paris, <i>France</i>	Cancer meeting with the French prime minister & pharmaceutical companies.
Nov 2012	Congress, Dublin, <i>Ireland</i>	24 <sup>th</sup> EORTC-NCI-AACR Symposium. Immune contexture, a novel paradigm for cancer.
Oct 2012	Congress, Bethesda, <i>USA</i>	SITC Tumor microenvironment meeting 2012. Immune contexture, a novel paradigm for cancer. (presented by Helen Angell)
Oct 2012	Seminar, Paris, <i>France</i>	BMS. The Immunoscope: a novel approach for the classification of cancer in the era of immunotherapies (symposium postponed)
Sep 2012	Congress, New York, <i>USA</i>	CRI cancer Symposium 2012 Immune contexture, a novel paradigm for cancer.
Sep 2012	Congress, Florence, <i>Italy</i>	Tumor microenvironment hasumi meeting. Immune contexture, a novel paradigm for cancer.
Sep 2012	Congress, Glasgow, <i>Scotland</i>	ECI European Immunology conference 2012. Immune contexture, a novel paradigm for cancer.
Jun 2012	Seminar, Philadelphia, <i>USA</i>	GSK. The immunoscope: a novel approach for the classification of cancer in the era of immunotherapies
Jun 2012	Congress, Tatra, <i>Slovakia</i>	EFIS-EJI 10 <sup>th</sup> Immunology conference 2012. Immune contexture, a novel paradigm for cancer.
May 2012	Seminar, Bruxelles, <i>Belgium</i>	GSK. The immunoscope: a novel approach for the classification of cancer in the era of immunotherapies
May 2012	Congress, Mainz, <i>Germany</i>	AACR 10 <sup>th</sup> Annual Meeting. The immunoscope: a novel approach for the classification of cancer in the era of immunotherapies
May 2012	Congress, Hammamet, <i>Tunisia</i>	2 <sup>nd</sup> Congrès International Maghrebin d'Immunologie. Intratumoral immune reaction : A novel paradigm for cancer.
Apr 2012	Congress, N <sup>al</sup> Harbor, <i>USA</i>	CIC Annual Meeting 2012. The immunoscope: a novel approach for the classification of cancer in the era of immunotherapies
Apr 2012	Congress, Prague, <i>Czech</i>	European Multidisciplinary Colorectal Cancer Congress (EMCCC) 2012. Prognostic significance of local immune responses.
Apr 2012	Congress, Chicago, <i>USA</i>	American Association for Cancer Research, AACR Annual Meeting 2012. Immune contexture, a novel paradigm for cancer.
Mar 2012	Congress, Chicago, <i>USA</i>	TVACT 2012, A novel of cancer based on the Immunoscope.
Mar 2012	Congress, Tuscon, <i>USA</i>	Roche symposium 2012. The science behind the Immunoscope.
Mar 2012	Congress, Tuscon, <i>USA</i>	Roche symposium 2012. A novel of cancer based on the Immunoscope.
Mar 2012	Seminar, Lyon, <i>France</i>	Immune contexture, a novel paradigm for cancer.
Mar 2012	Seminar, Rouen, <i>France</i>	Immune contexture, a novel paradigm for cancer
Feb 2012	Congress, Naples, <i>Italy</i>	1 <sup>st</sup> Immunoscope task force meeting. The science behind the Immunoscope

Feb 2012	Congress, Naples, <i>Italy</i>	1 <sup>st</sup> Immunoscore task force meeting. A novel of cancer based on the Immunoscore
Jan 2012	Congress, Mumbai, <i>India</i> ,	31 <sup>st</sup> Annual Convention of Indian Association for Cancer Research. Immune contexture, a novel paradigm for cancer.
Jan 2012	Seminar, Bangalore, <i>India</i> ,	TNM staging : T is for T cells & M is for Memory
Jan 2012	Seminar, Pune, <i>India</i> ,	Immune contexture, a novel paradigm for cancer
Jan 2012	Seminar, Bruxelles, <i>Belgium</i>	Erasmus Hospital, TNM staging, T is for T cells and M is for Memory.